12. Cheung NK: Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 
38:425, 1991. 
13. Sturm E, Braakman E, Fisch P, Vreugdenhil RJ, Sondel P, Bolhuis RL: Human V 
gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi 
Burkitt’s lymphoma cells. J Immunol 145:3202, 1990. 
14. Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, Voss SD, Morrissey 
LW, Demars R, Welch WJ, et al : Recognition by human V gamma 9/V delta 2 T cells 
of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science 250:1269, 1990. 
15. Foreman NK, Rill DR. Coustan-Smith E, Douglass EC, Brenner MK. Mechanisms of 
selective killing of neuroblastoma cells by natural killer cells and lymphokine activated 
killer cells. Potential for residual disease eradication. Cancer Res In press 1992. 
16. Main EK, Lampson LA, Hart MK, et al : Human neuroblastoma cell lines are 
susceptible to lysis by natural killer but not cytotoxic T lymphocytes. J Immunol 
135:242, 1985. 
17. Reynolds JV, Shou J, Choi H, Sigal R, Ziegler MM, Daly JM: The influence of natural 
killer cells in neuroblastoma. Arch Surg 124:235, 1989. 
18. Cheung NK, Burch L, Kushner BH, Munn DH: Monoclonal antibody 3F8 can effect 
durable remissions in neuroblastoma (NB) patients (PTS) refractory to chemotherapy: 
a phase II trial. Proc Annu Meet Am Assoc Cancer Res 31:A1705, 1990 (abstr.). 
19. Cheung NK, Medof ME, Munn D: Immunotherapy with GD2 specific monoclonal 
antibodies. Prog Clin Biol Res 271:619, 1988. 
20. Cheung NK, Yeh SD, Gulti S, Burch L, Kushner BH, Larson S: 131I-3F8 targeted 
radiotherapy of neuroblastoma (NB): a phase I clinical trial. Proc Annu Meet Am 
Assoc Cancer Res 31:A1686, 1990 (abstr.). 
21. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW: Complement killing of 
human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)’-2-cobra 
venom factor conjugate are equally cytotoxic. Mol Immunol 27:957, 1990. 
22. Munn DH, Cordon-Cardo C, Yeh SD, Kushner BH, Cheung NK: Therapy of 
neuroblastoma with GD2 specific monoclonal antibody 3F8, in Oettgen HF (ed): 
Gangliosides and Cancer, New York, VCH, 1989, p 259. 
23. Yu AL, Gillies SD, Reisfeld RA: Phase I clinical trial of Chl4.18 in patients with 
refractory neuroblastoma. Proc ASCO 10:1118, 1991. 
Recombinant DNA Research, Volume 15 
[763] 
